Member Info for WeTookPelham

I also followed the tempest therapeutics news with some interest also, an insane move in the SP.

But looking at their actual data release:

"Patients treated with the triple therapy had median progression-free survival of seven months, versus 4.3 months for those treated only with Tecentriq and Avastin, Tempest said."

https://www.marketwatch.com/story/tempest-therapeutics-shares-head-back-to-earth-after-4-000-gain-be2f6b73

Whilst probably difficult to compare like for like (different targets etc) the recent SCIB1 results are far far more impressive are they not? Relatively speaking.

As others have mentioned if Scancell were in the USA and they released that SCIB1 RNS there, can you imagine the move?*

*I don't fully understand the "poison pill" stock change however and how much it was a factor in the move.

Darkprince you said the same thing when the audit results date change rns was announced, then you went all quiet as the price recovered 😂.

You're game is obvious.

Haven't you got a bridge you should be sitting under?

.

Interesting that the CFO is also presenting?

Cannot buy anywhere between 1000-30000 shares atm, not tried higher amounts.

Ruckrover - likewise, don't let your obsession with inanaco cloud your view.

Likewise Dibs61, grateful for the opportunity a short while ago.

It's 14.475p to buy a 1000 for me on my broker atm.

Purely IMO those dates are too much of a coincidence. If it's related to a shortage of auditors, the specific two week seems odd as does the very last min reschedule.

@ciaskin - my thoughts exactly.

Interesting that it was the ASTUTE that raised this notion.

This reply makes more sense, basically why hire a deal maker? And aren't the scib results unprecedented?

"10/10/2023

08:08 rogerbridge: MWith the recent executive appointments, we now have dealmakers who have a vast experience within the industry.

Marcus has highlighted the opportunities to fund the company through licensing. It’s debatable if there will be a need for funding through an issue of shares."

IMO, and as mentioned before, the de-ramping is getting more and more subtle and nuanced lately, must be some worried types out there.

Https://sifted.eu/articles/ma-advisors-explainer-acquisitions-2023

Very interesting article IMO.

"PharmaJet Partner, Scancell, Announces Positive Data from the First Stage of its Phase 2 Trial of Advanced Melanoma DNA Vaccine delivered Needle-free

SCOPE trial surpasses its first milestone with an 82% response rate."

https://www.businesswire.com/news/home/20230928299663/en/PharmaJet-Partner-Scancell-Announces-Positive-Data-from-the-First-Stage-of-its-Phase-2-Trial-of-Advanced-Melanoma-DNA-Vaccine-delivered-Needle-free

"Needle-free delivery is favored by patients.

If confirmed in a larger cohort, these data could result in significantly improved care for melanoma patients."

...are you not going call out crackin for his price prediction? He hasn't shown any analysis or reasoning (yet again). You jumped on Ahananda's back immediately when dared to make a prediction to the upside.

Funny that.

...and no major Friday/weekend profit taking despite 60% rise over the last week.

Promising and unusual?

Nice spot CW.

9 months...pfft... Scancell will in the quids by then ;-)

"

- A useful Active licensing discussions ongoing.***⭐

- Scib-1 clearing bulky tumours.....fantastic

-Looking incredibly good that tumours are staying shrunk.

- Lindy "Stunning results"

- We EXPECT to see improved Modi-1 results in combination with CPI

- 3 Three biotech companies are negotiating re Glymabs/Avidimab atm*** ⭐

- Needle free is a big hit. Systemic administration (arm or leg ) gets at tumours in lungs and liver.

"

I don't believe those points I've highlighted with stars have had the debate they deserve i.e. "3 X biotech companies are negotiating" and "useful Active licensing discussions".

Surely quite significant?

Https://www.targetedonc.com/view/phase-2-scope-trial-of-scib1-achieves-positive-orr-in-advanced-melanoma

Https://www.trinitydelta.org/research-notes/scib1-scope-study-shows-a-striking-82-orr/

Again, apologies if already posted? But headlines like '...striking 82% OOR' are significant IMO.